Regeneron Pharmaceuticals Inc.Regeneron Pharmaceuticals Inc.Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc.

No trades
See on Supercharts

Key facts today

Wolfe Research has started coverage of Regeneron Pharmaceuticals, Inc. with an 'Outperform' rating and a price target of $1,150. Analyst targets for the company range from $800 to $1,230.
Analyze the impactAnalyze the impact
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪81.66 B‬EUR
38.8EUR
‪3.58 B‬EUR
‪11.88 B‬EUR
‪105.96 M‬
Beta (1Y)
0.65

About Regeneron Pharmaceuticals, Inc.


CEO
Leonard S. Schleifer
Headquarters
Tarrytown
Founded
1988
FIGI
BBG000HCZ2Q3
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Regeneron Pharmaceuticals Inc. stocks are traded under the ticker RGO.
We've gathered analysts' opinions on Regeneron Pharmaceuticals Inc. future price: according to them, RGO price has a max estimate of 1,164.61 EUR and a min estimate of 757.47 EUR. Watch RGO chart and read a more detailed Regeneron Pharmaceuticals Inc. stock forecast: see what analysts think of Regeneron Pharmaceuticals Inc. and suggest that you do with its stocks.
RGO reached its all-time high on Aug 29, 2024 with the price of 1,087.0 EUR, and its all-time low was 3.4 EUR and was reached on Apr 7, 2005. View more price dynamics on RGO chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Regeneron Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
Regeneron Pharmaceuticals Inc. is going to release the next earnings report on Jan 31, 2025. Keep track of upcoming events with our Earnings Calendar.
RGO earnings for the last quarter are 11.19 EUR per share, whereas the estimation was 10.50 EUR resulting in a 6.54% surprise. The estimated earnings for the next quarter are 10.55 EUR per share. See more details about Regeneron Pharmaceuticals Inc. earnings.
Regeneron Pharmaceuticals Inc. revenue for the last quarter amounts to ‪3.34 B‬ EUR, despite the estimated figure of ‪3.30 B‬ EUR. In the next quarter, revenue is expected to reach ‪3.57 B‬ EUR.
RGO net income for the last quarter is ‪1.20 B‬ EUR, while the quarter before that showed ‪1.34 B‬ EUR of net income which accounts for −9.96% change. Track more Regeneron Pharmaceuticals Inc. financial stats to get the full picture.
No, RGO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 16, 2024, the company has ‪13.45 K‬ employees. See our rating of the largest employees — is Regeneron Pharmaceuticals Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Regeneron Pharmaceuticals Inc. EBITDA is ‪4.14 B‬ EUR, and current EBITDA margin is 36.36%. See more stats in Regeneron Pharmaceuticals Inc. financial statements.
Like other stocks, RGO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Regeneron Pharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.